A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

The New England journal of medicine

Volumn 376, Issue 18, 2017, Pages e38-

  Fitzgerald, Kevin ^a   Kallend, David ^b   Simon, Amy ^a  

^a ALNYLAM PHARMACEUTICALS   (United States)

^b MEDICINES COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SERINE PROTEINASE;

GENETICS; HUMAN; METABOLISM; RNA INTERFERENCE; RNAI THERAPEUTICS;

CHOLESTEROL, LDL; HUMANS; PROPROTEIN CONVERTASES; RECEPTORS, LDL; RNA INTERFERENCE; RNAI THERAPEUTICS; SERINE ENDOPEPTIDASES;

EID: 85019032612     PISSN: None     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1703361     Document Type: Letter

References (0)